Introduction
============

Adult patients receiving anti-TNFα treatment are at increased risk for developing tuberculosis (TB). Few data have been published in the pediatric population.

Objectives
==========

We describe the occurrence of latent tuberculosis infection (LTI) and TB in children and adolescents treated with anti-TNFα agents.

Methods
=======

Cohort observational study including pediatric patients receiving anti-TNFα agents in a tertiary-care pediatric hospital. LTI is ruled out by the implementation of anti-TNFα drugs by tuberculin skin test (TST) and, from March 2012, QuantiFERON Gold-In Tube^®^test (QTF). Along treatment, patients are evaluated periodically for TB using history and physical examination, but TST/QTF are not systematically repeated.

Results
=======

The final cohort consisted of 261 anti-TNFα treatments in 221 patients (56.1% female), of whom 51.7%/31.%/17.2% treated with etanercept/adalimumab/infliximab, respectively, for a variety of rheumatic diseases (75.6%), inflammatory bowel disease (20.8%) and inflammatory eye diseases (3.6%). The mean(SD) age at diagnosis of the primary condition was 7.2(4.6) years and the duration of the disease before implementing the anti-TNFα agent was 3.0(3.3) years. The total follow-up time under anti-TNFα treatment was 614 patients-year; mean(SD) time per patient: 2.8(2.2) years.

LTI was diagnosed in 3 adolescent girls (prevalence rate: 1.4%; 95%CI: 0-2.9) affected with juvenile idiopathic arthritis, who received isoniazid chemoprophylaxis and were later treated with anti-TNFα, without incidences. QTF tested positive in all three patients, while TST was positive in only one of them. No incident cases of TB were observed.

Conclusion
==========

In our study, the prevalence of LTI (1.4%) was similar to that reported in population screening studies in Spain and no incident cases of TB were observed.
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